Document Detail

Severe dermatologic reactions at multiple sites after paclitaxel administration.
MedLine Citation:
PMID:  14742758     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To report a case of a severe dermatologic reaction at the infusion site, as well as at multiple distant sites, after paclitaxel administration. CASE SUMMARY: A 53-year-old white male with cancer of the base of the tongue was treated with paclitaxel 100 mg/m2 infused over 3 hours and carboplatin dosed at an AUC of 6 mg/mL x min infused over 30 minutes via a peripheral vein on the left arm. After 4 doses of paclitaxel, the patient developed erythematous patches on both forearms and both thighs. The lesions on the left arm worsened into a necrotic ulcer, exposing underlying tissues. All of the lesions healed after paclitaxel was withheld from subsequent cycles. Based on the Naranjo probability scale, it is probable that paclitaxel was the causative agent for these lesions. DISCUSSION: Most of the previously reported paclitaxel-induced dermatologic reactions occurred following extravasation. There are few reports of generalized dermatologic rashes. These rashes are thought to be due to delayed hypersensitivity either to paclitaxel or the solubilizing agents. Our patient had dermatologic toxicity at the infusion site, as well as at multiple other sites, that developed about 6 weeks after the first paclitaxel infusion. CONCLUSIONS: Generalized dermatologic toxicity after paclitaxel administration is uncommon and seems to be immunologically mediated. This toxicity could be secondary to paclitaxel or the additives. The use of paclitaxel is increasing in various malignancies. Newer formulations are under development. Until these formulations are available, clinicians should report any dermatologic reactions in order to identify the cause of toxicity and develop safer administration technique.
Rakesh Beri; Fred R Rosen; Michael J Pacini; Swati R Desai
Related Documents :
10210548 - Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: ...
15711828 - Phase i study of the novel taxane ct-2103 in patients with advanced solid tumors.
12477998 - Phase ii trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma.
18521208 - Phase ii study of paclitaxel in patients with soft tissue sarcomas.
17092548 - A new prognostic model for figo stage 1 epithelial ovarian cancer.
17762758 - High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2003-12-19
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  38     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-01-26     Completed Date:  2004-05-11     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  238-41     Citation Subset:  IM    
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612-7230, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / adverse effects*,  therapeutic use
Carcinoma, Squamous Cell / drug therapy
Middle Aged
Paclitaxel / adverse effects*,  therapeutic use
Skin Ulcer / chemically induced*,  pathology
Tongue Neoplasms / drug therapy
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Possible gatifloxacin-induced seizure.
Next Document:  Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide.